MK-3120
Sponsors
Merck Sharp & Dohme LLC
Conditions
Advanced Solid TumorsAdvanced/metastatic solid tumor diseaseBladder CancerHigh-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumorsMalignant NeoplasmUrinary Bladder NeoplasmsUrothelial CarcinomaUrothelial carcinoma
Phase 1
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Active, not recruitingNCT05562830
Start: 2022-11-16End: 2028-06-20Target: 48Updated: 2026-04-02
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RecruitingNCT06818643
Start: 2025-03-25End: 2031-03-25Target: 270Updated: 2026-02-19
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants with Advanced Solid Tumors
RecruitingCTIS2024-516817-19-00
Start: 2025-05-23Target: 83Updated: 2025-09-08
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
RecruitingNCT07222488
Start: 2025-12-09End: 2029-02-28Target: 45Updated: 2026-04-02
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RecruitingNCT07232602
Start: 2026-02-09End: 2030-10-18Target: 55Updated: 2026-04-02
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
Not yet recruitingCTIS2025-520467-40-00
Target: 32Updated: 2026-01-09
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04–Substudy 04D
Not yet recruitingCTIS2025-522253-19-00
Target: 6Updated: 2026-02-03